在质母细胞瘤治疗方法中的血管生成
Agnieszka Nowacka1, Maciej Śniegocki1, Wojciech Smuczyński2
1Department of Neurosurgery, Nicolas Copernicus University in Toruń, Collegium Medicum in Bydgoszcz, ul. Curie Skłodowskiej 9, 85-094 Bydgoszcz, Poland.
Cells
|March 26, 2025
概括
质母细胞瘤治疗面临着由于瘤耐药性的挑战. 需要新的策略来克服补偿性血管生成并改善这种侵袭性脑癌的存活率.
科学领域:
- 神经瘤学神经瘤学
- 癌症生物学 癌症生物学
- 分子医学是分子医学.
背景情况:
- 质母细胞瘤 (GBM) 是一种具有不良预后的侵袭性脑瘤.
- 由血管内皮生长因子-A (VEGF-A) 驱动的瘤血管生成对于GBM生长至关重要.
- 针对VEGF的抗血管性疗法在改善GBM患者的整体存活率方面表现出有限的有效性.
研究的目的:
- 审查目前用于GBM治疗的抗血管原剂.
- 分析GBM中抗血管性疗法耐药性的机制.
- 探索新的策略,以提高抗血管性治疗对GBM的有效性.
主要方法:
- 对质母细胞瘤的抗血管原性疗法的综合文献综述.
- 对VEGF向药物的临床前和临床研究的分析.
- 研究获得性耐药性和补偿性血管生成的机制.
主要成果:
- 贝瓦西祖马布和其他VEGF抑制剂未能显著改善GBM的整体存活率.
- 补偿性血管新生通路出现,绕过直接的VEGF抑制.
- 抵抗机制需要探索替代或组合治疗策略.
结论:
- 目前针对GBM的抗血管性疗法受到抵抗机制的限制.
- 了解和克服这些抗药性途径对于开发有效的治疗方法至关重要.
- 未来的研究应该专注于组合疗法和新的目标,以改善GBM患者的治疗结果.
相关概念视频
Mechanism of Angiogenesis
5.2K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.2K
Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Tumor Immunotherapy
450
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
450


